Contrast agent-free sonoporation: The use of an ultrasonic standing wave microfluidic system for the delivery of pharmaceutical agents |
| |
| Authors: | Carugo Dario Ankrett Dyan N Glynne-Jones Peter Capretto Lorenzo Boltryk Rosemary J Zhang Xunli Townsend Paul A Hill Martyn |
| |
| Institution: | 1Bioengineering Group, Engineering Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom;2Electromechanical Engineering Group, Engineering Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom;3Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom |
| |
| Abstract: | Sonoporation is a useful biophysical mechanism for facilitating the transmembrane delivery of therapeutic agents from the extracellular to the intracellular milieu. Conventionally, sonoporation is carried out in the presence of ultrasound contrast agents, which are known to greatly enhance transient poration of biological cell membranes. However, in vivo contrast agents have been observed to induce capillary rupture and haemorrhage due to endothelial cell damage and to greatly increase the potential for cell lysis in vitro. Here, we demonstrate sonoporation of cardiac myoblasts in the absence of contrast agent (CA-free sonoporation) using a low-cost ultrasound-microfluidic device. Within this device an ultrasonic standing wave was generated, allowing control over the position of the cells and the strength of the acoustic radiation forces. Real-time single-cell analysis and retrospective post-sonication analysis of insonated cardiac myoblasts showed that CA-free sonoporation induced transmembrane transfer of fluorescent probes (CMFDA and FITC-dextran) and that different mechanisms potentially contribute to membrane poration in the presence of an ultrasonic wave. Additionally, to the best of our knowledge, we have shown for the first time that sonoporation induces increased cell cytotoxicity as a consequence of CA-free ultrasound-facilitated uptake of pharmaceutical agents (doxorubicin, luteolin, and apigenin). The US-microfluidic device designed here provides an in vitro alternative to expensive and controversial in vivo models used for early stage drug discovery, and drug delivery programs and toxicity measurements. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
